{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.42","upperLimit":"14.75","value":"12.52"},{"groupId":"OG001","lowerLimit":"2.86","upperLimit":"5.52","value":"3.68"}]}],"title":"Ki67 <=2% (n: 7, 17)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.55","upperLimit":"16.59","value":"10.94"},{"groupId":"OG001","lowerLimit":"3.78","upperLimit":"13.83","value":"8.48"}]}],"title":"2% <Ki67 <=5% (n: 24, 13)"},{"categories":[{"measurements":[{"comment":"Upper boundary of the 95% (Confidence Interval (CI) was not computable","groupId":"OG000","lowerLimit":"5.59","upperLimit":"NA","value":"7.69"},{"groupId":"OG001","lowerLimit":"2.79","upperLimit":"5.55","value":"3.15"}]}],"title":"Ki67 >5% (n: 20, 22)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"The level of Ki 67 expression for evaluable tumor samples were analyzed towards progression free survival (PFS) as per local investigator assessment. The Ki-67 protein is a cellular marker for proliferation. It is strictly associated with cell proliferation. During interphase, the Ki-67 antigen can be exclusively detected within the cell nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes. Baseline Ki 67 levels were categorized as: less than or equal to 2%, \\> 2% to less than or equal to 5% and \\> 5%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG000","title":"Everolimus 10 mg/Day"},{"description":"Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients who were randomized.","reportingStatus":"POSTED","timeFrame":"Time from randomisation to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomised, 17 August 2007, until cut-off date 28 February 2010","title":"Progression Free Survival According to Ki-67 Levels Categorized as: Less Than or Equal to 2%, > 2% to Less Than or Equal to 5% and > 5%","type":"SECONDARY","unitOfMeasure":"Months"}